申请人:Janssen Pharmaceutica NV
公开号:US10118900B2
公开(公告)日:2018-11-06
The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
本发明涉及苯并咪唑衍生物、含有苯并咪唑衍生物的药物组合物及其在治疗由 CB-1 受体介导的紊乱和病症中的用途;更具体地说,是在治疗对 CB-1 受体的反向激动有反应的紊乱和病症中的用途。更具体地说,本发明的化合物可用于治疗代谢紊乱。